Cannara Biotech Wraps Up Medican Organic Acquisition

MONTREAL – Cannara Biotech Inc. announced the closing of a transaction to acquire all of the shares of Medican Organic Inc. for an aggregate purchase price of $2.8 million. On the surface, that’s a modest sum. In context, it’s the final piece of a five-year consolidation play that Cannara has been assembling since 2021.

This acquisition completes Cannara’s previous purchase of the Valleyfield cultivation and manufacturing facility from Medican in June, 2021. Back then, the original transaction carried a price tag of $27 million, a facility deal that gave Cannara the physical infrastructure. What it did not give them was the corporate entity behind it. This week’s close fixes that.

The acquisition was finalized following Medican’s exit from proceedings under the Companies’ Creditors Arrangement Act (CCAA) involving Medican’s parent company – BZAM Ltd., formerly known as The Green Organic Dutchman. Its financial distress opened a door for Cannara to move at a price that would have been unthinkable in the sector’s earlier, more euphoric years.

What Cannara is actually buying here is operational knowledge. Since the initial transaction in 2021, Medican has continued to refine its operating procedures, cultivation practices and post-harvest know-how, including unique extract manufacturing processes, providing Cannara with incremental operational expertise to support its continued growth. In an industry where the gap between cultivation capacity and actual execution quality has tripped up many a well-funded operator, institutional know-how is a real and underappreciated asset.

Cannara owns two massive facilities based in Québec spanning over 1,600,000 sq. ft., providing the Company with 100,000 kg of potential annualized cultivation output. Quebec’s electricity rates, among the lowest on the continent, give the company a structural cost advantage that few Canadian producers can replicate. Folding Medican’s corporate shell and process expertise into that infrastructure is less about adding square footage and more about tightening the operational machine.

CEO Zohar Krivorot described the move as positioning the company to execute on its strategic plan. Far from being a mere press release formality, this statement of intent comes from a company that has largely stayed out of the sector’s noise while methodically building scale.

In the wider context of the Canadian Сannabis market, this deal serves as a reminder of something that many had predicted in 2020 and 2021 and that is still very much underway – consolidation; just slower and increasingly driven by distressed asset economics rather than bold strategic vision. Cannara paid $2.8 million for something it had been operating alongside for four years. That kind of patience, in an industry that burned through capital at a remarkable rate, is now starting to look like competitive advantage.